title: Therapeutic effects of mifepristone combined with Gestrinone on patients with endometriosis.
abstract: OBJECTIVE
  To evaluate the clinical therapeutic effects of mifepristone combined with gestrinone on patients with endometriosis.
  
  
  METHODS
  A total of 150 endometriotic patients treated in our hospital between January 2014 and December 2015 were randomly divided into a control group and a treatment group (n=75). The control group began to orally take gestrinone capsules on the second day after menstruation started (2.5 mg/time, twice/week). The treatment group orally took mifepristone tablets (12.5 mg/time, once/day), and the dosage and administration of gestrinone capsules were the same as those of the control group. After 24 weeks of consecutive treatment, the clinical therapeutic effects of the two groups were assessed, and the pelvic symptom score, clinical sign score, serum sex hormone levels and pregnancy outcomes were compared.
  
  
  RESULTS
  The total effective rates of control and treatment groups were 77.3% and 90.7% respectively, between which the difference was statistically significant (P<0.05). After treatment, the scores of pelvic symptoms (dysmenorrhea, dyspareunia, pelvic pain) and clinical signs (pelvic tenderness, induration) significantly reduced (P<0.05). Each score of the treatment group decreased more significantly than that of the control group did (P<0.05). The serum follicle hormone, luteinizing hormone, estrogen and progesterone levels were significantly lower than those before treatment (P<0.05). Each level of the treatment group dropped more significantly than that of the control group did (P<0.05). The pregnancy rates in the 6th and 12th months of follow-up were 28.0% and 13.3% in the control group respectively, and 42.7% and 29.3% in the treatment group respectively. Such rates of the two groups were significantly different at each follow-up time point (P<0.05).
  
  
  CONCLUSIONS
  Mifepristone combined with gestrinone had satisfactory clinical therapeutic effects on endometriosis by reducing hormone levels and improving pregnancy outcomes. Therefore, this regimen is worthy of promotion and application in clinical practice.
authors.affiliation: Hui-Ling Xue, Department of Obstetrics and Gynecology, Affiliated Hospital of Hebei University, Baoding 071000, Hebei Province, P. R. China.
authors.forename: Hui-Ling
authors.initials: HL
authors.lastname: Xue
authors.affiliation: Ning Yu, Department of Obstetrics and Gynecology, People's Hospital of Yi County, Baoding 074200, Hebei Province, P. R. China.
authors.forename: Ning
authors.initials: N
authors.lastname: Yu
authors.affiliation: Jing Wang, Department of Obstetrics and Gynecology, Affiliated Hospital of Hebei University, Baoding 071000, Hebei Province, P. R. China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Wan-Jiao Hao, Department of Obstetrics and Gynecology, Affiliated Hospital of Hebei University, Baoding 071000, Hebei Province, P. R. China.
authors.forename: Wan-Jiao
authors.initials: WJ
authors.lastname: Hao
authors.affiliation: Ye Li, Department of Obstetrics and Gynecology, Affiliated Hospital of Hebei University, Baoding 071000, Hebei Province, P. R. China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Li
authors.affiliation: Mei-Yun Liu, Department of Obstetrics and Gynecology, Affiliated Hospital of Hebei University, Baoding 071000, Hebei Province, P. R. China.
authors.forename: Mei-Yun
authors.initials: MY
authors.lastname: Liu
keywords: Endometriosis; Gestrinone; Mifepristone